Highland Capital Management 13F: Cuts AbbVie (ABBV) Stake by $3M
Key Points
- Highland Capital Management reduced its position in AbbVie by 11,601 shares, bringing its total to 31,975 shares worth approximately $8.36 million.
- The fund's stake now represents 1.0% of its total reported value of $833.1 million and ranks 14th among its 415 holdings.
- AbbVie shares recently traded at $286.74, about equal to the closing price on the filing date, and above both the 50-day and 200-day moving averages.
Get AbbVie text alerts
We text you when insiders, Congress, analysts or big funds move on $ABBV.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated AbbVie Inc. alert may contain errors. Disclosures
Highland Capital Management cut its stake in AbbVie Inc. (ABBV) by 11,601 shares in a filing on October 26, 2026. The fund now holds 31,975 shares valued at about $8.36 million.
ABBV
AbbVie Inc.
What Changed in Highland Capital Management's AbbVie Position
Highland Capital reduced its position by 11,601 shares, which is a 26.6% decrease from its previous holding of 43,576 shares.
Where AbbVie Fits in Highland Capital Management's Portfolio
AbbVie now makes up 1.0% of Highland's total reported value of $833.1 million. The stock ranks 14th among the fund's 415 positions.
Other Institutional Activity in AbbVie
Several other funds have also adjusted their positions in AbbVie. Perigon Wealth Management reduced its holdings by 17,805 shares, holding 93,671 shares worth about $24.5 million. In contrast, Sepio Capital increased its stake by 619,274 shares, bringing its total to 749,451 shares valued at approximately $196.0 million.
AbbVie Inc. Stock Up 0.4%
Shares of AbbVie recently traded at $286.74, which is about equal to the closing price on October 26, 2026. The stock is currently above its 50-day moving average by 7.4% and its 200-day moving average by 21.6%. However, it is 1.6% below its 52-week high of $291.40.
Recent Earnings
For the trailing twelve months, AbbVie reported revenue of approximately $64.4 billion and earnings per share (EPS) of $3.55. The company has shown a revenue growth of 10.2% year-over-year. AbbVie is set to announce its next earnings on October 30, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
4 analysts raised price targets.
-
EPS & revenue
EPS met estimates. Revenue met estimates.
-
Profit surprise
EBITDA missed by 42 percent. Operating income missed by 72 percent.
-
Pre-earnings setup
Expectations were about average.
-
Analyst signal
4 target raises.
-
Earnings quality
Gross margin up 1.9 points. Operating margin up 3.6 points. Positive free cash flow.
Earnings Call Summary
AbbVie delivered strong first quarter results with $15 billion in sales and earnings per share of $2.65, beating expectations. Skyrizi sales hit $4.5 billion with 29 percent growth in psoriasis and inflammatory bowel disease markets. Rinvoq brought in $2.1 billion with 20 percent growth across rheumatology and gastroenterology, and the company is preparing to launch the drug in alopecia areata and vitiligo later this year.
Guidance The company raised full year earnings per share guidance to between $14.08 and $14.28, up $0.12. They now expect about $67.3 billion in total sales for the year. They also raised guidance for second quarter to about $16.7 billion in revenue and earnings per share between $3.74 and $3.78.
Fine but not compelling. Acceptable results that likely do not create a meaningful forward reset.
Dividend
AbbVie offers an annual dividend of $6.92 per share, resulting in a yield of 2.41%. The dividend payout ratio stands at 190.4%, indicating the percentage of earnings paid to shareholders as dividends.
Insider Buying and Selling at AbbVie Inc.
Recently, several insiders sold shares of AbbVie. Perry C. Siatis, the General Counsel, sold 22,381 shares on February 25, 2026, at an average price of $230, totaling about $5.15 million. Additionally, Nicholas Donoghoe, an officer, sold 32,710 shares on August 14, 2026, valued at approximately $8.18 million.
Analysts Set New Price Targets
On October 9, 2026, UBS maintained a "Neutral" rating with a price target of $275. Guggenheim reiterated a "Buy" rating with a target of $288, while RBC Capital also reiterated an "Outperform" rating with a target of $280. The consensus rating for AbbVie is currently "Buy" with a mean price target of approximately $284.79.
About AbbVie
AbbVie Inc. is a biopharmaceutical company based in North Chicago, Illinois. It focuses on research and development, manufacturing, and selling various medicines and therapies worldwide, including treatments for autoimmune diseases and cancers.
Bottom Line
Highland Capital's reduction in AbbVie shares is part of a broader trend among institutional investors adjusting their positions. Keep an eye on AbbVie's upcoming earnings report on October 30, 2026, for more insights into the company's performance.
Related Filing Alerts
Source: Highland Capital Management's 13F filing on $ABBV (Oct 26, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Written by software, not financial advice. How we make alerts